HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Antengene (6996.HK) 22H1-Defective Business Model and Uncompetitive Pipeline; Bearish on the Outlook

Investment Opportunities in China Medical Device Industry

Microport Scientific (853.HK) - It Is a Good Time to See Some Concerns

Antengene - Insights on Pipeline and Valuation

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<p>In February, 2021, China’s National Medical Products Administration (NMPA) granted priority review to the New Drug Application (NDA) for ATG-010 (selinexor, XPOVIO), a first-in-class selective inhibitor of nuclear export (SINE) compound, for the treatment of patients with relapsed/refractory multiple myeloma (rrMM). Recently, <a href="https://www.smartkarma.com/entities/antengene-corp-ltd" target="_blank" data-smartkarma-citation="entities:29705:1" rel="noopener">Antengene (6996 HK)</a> announced that the NMPA has also approved the Investigational New Drug (IND) application for a Phase III clinical trial designed to evaluate the safety and efficacy of selinexor (XPOVIO) in the treatment of advanced or recurrent endometrial cancer (the SIENDO trial). In fact, selinexor would be the first-to-market product in the pipeline and is also a core product for the Company. So, how is this product and what is the business prospect of Antengene?</p>

In February, 2021, China’s National Medical Products Administration (NMPA) granted priority review to the New Drug Application (NDA) for ATG-010 (selinexor, XPOVIO), a first-in-class selective inhibitor of nuclear export (SINE) compound, for the treatment of patients with relapsed/refractory multiple myeloma (rrMM). Recently, Antengene (6996 HK) announced that the NMPA has also approved the Investigational New Drug (IND) application for a Phase III clinical trial designed to evaluate the safety and efficacy of selinexor (XPOVIO) in the treatment of advanced or recurrent endometrial cancer (the SIENDO trial). In fact, selinexor would be the first-to-market product in the pipeline and is also a core product for the Company. So, how is this product and what is the business prospect of Antengene?

Antengene (6996.HK) - Still Has a Long Way to Go Despite the New Progress On Selinexor